[HENGYUAN] QoQ Cumulative Quarter Result on 31-Dec-2021 [#4]

Stock
[HENGYUAN] HENGYUAN REFINING COMPANY BERHAD
Announcement Date
28-Feb-2022
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2021
Quarter
31-Dec-2021 [#4]
Profit Trend
QoQ- 185.13%
YoY- -67.06%
Quarter Report
Latest QR
Upcoming QR
HENGYUAN's Result
HENGYUAN's Financial Summary
View:
Show?
Cumulative Result
30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 CAGR
Revenue 16,878,213 11,847,418 4,953,258 12,006,040 7,949,400 4,699,402 2,197,892 288.75%
PBT 88,394 982,535 85,278 127,702 -102,495 -46,891 33,572 90.56%
Tax -13,932 -267,594 -37,822 -45,030 5,384 3,823 -17,264 -13.30%
NP 74,462 714,941 47,456 82,672 -97,111 -43,068 16,308 174.97%
-
NP to SH 74,462 714,941 47,456 82,672 -97,111 -43,068 16,308 174.97%
-
Tax Rate 15.76% 27.24% 44.35% 35.26% - - 51.42% -
Total Cost 16,803,751 11,132,477 4,905,802 11,923,368 8,046,511 4,742,470 2,181,584 289.53%
-
Net Worth 1,328,369 1,576,380 1,988,490 2,051,970 1,821,090 2,025,330 2,143,349 -27.28%
Dividend
30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 CAGR
Div 30,000 30,000 - - - - - -
Div Payout % 40.29% 4.20% - - - - - -
Equity
30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 CAGR
Net Worth 1,328,369 1,576,380 1,988,490 2,051,970 1,821,090 2,025,330 2,143,349 -27.28%
NOSH 300,000 300,000 300,000 300,000 300,000 300,000 300,000 0.00%
Ratio Analysis
30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 CAGR
NP Margin 0.44% 6.03% 0.96% 0.69% -1.22% -0.92% 0.74% -
ROE 5.61% 45.35% 2.39% 4.03% -5.33% -2.13% 0.76% -
Per Share
30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 CAGR
RPS 5,626.07 3,949.14 1,651.09 4,002.01 2,649.80 1,566.47 732.63 288.75%
EPS 24.82 238.31 15.82 27.56 -32.37 -14.36 5.44 174.83%
DPS 10.00 10.00 0.00 0.00 0.00 0.00 0.00 -
NAPS 4.4279 5.2546 6.6283 6.8399 6.0703 6.7511 7.1445 -27.28%
Adjusted Per Share Value based on latest NOSH - 300,000
30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 CAGR
RPS 5,626.65 3,949.55 1,651.26 4,002.43 2,650.07 1,566.63 732.71 288.75%
EPS 24.82 238.34 15.82 27.56 -32.37 -14.36 5.44 174.83%
DPS 10.00 10.00 0.00 0.00 0.00 0.00 0.00 -
NAPS 4.4284 5.2551 6.629 6.8406 6.0709 6.7518 7.1452 -27.28%
Price Multiplier on Financial Quarter End Date
30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 CAGR
Date 30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 -
Price 4.11 4.85 3.97 3.87 4.34 4.82 5.20 -
P/RPS 0.07 0.12 0.24 0.10 0.16 0.31 0.71 -78.62%
P/EPS 16.56 2.04 25.10 14.04 -13.41 -33.57 95.66 -68.90%
EY 6.04 49.14 3.98 7.12 -7.46 -2.98 1.05 220.70%
DY 2.43 2.06 0.00 0.00 0.00 0.00 0.00 -
P/NAPS 0.93 0.92 0.60 0.57 0.71 0.71 0.73 17.50%
Price Multiplier on Announcement Date
30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 CAGR
Date 29/11/22 30/08/22 30/05/22 28/02/22 26/11/21 27/08/21 28/05/21 -
Price 4.55 5.35 6.70 4.28 3.86 4.47 5.68 -
P/RPS 0.08 0.14 0.41 0.11 0.15 0.29 0.78 -78.05%
P/EPS 18.33 2.24 42.36 15.53 -11.92 -31.14 104.49 -68.62%
EY 5.46 44.54 2.36 6.44 -8.39 -3.21 0.96 218.28%
DY 2.20 1.87 0.00 0.00 0.00 0.00 0.00 -
P/NAPS 1.03 1.02 1.01 0.63 0.64 0.66 0.80 18.33%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment